Measurement based care for Manic Disorder

Phase-Based Progress Estimates
Manic Disorder
Measurement based care - Other
All Sexes
What conditions do you have?

Study Summary

This trial will compare the effectiveness of measurement-based care to enhanced usual care in people with bipolar disorder. The main hypothesis is that treatment adjustments will occur more often in the MBC group than the enhanced usual care group. The exploratory hypothesis is that symptoms of bipolar disorder will decrease more in the MBC group than the enhanced usual care group.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: 6 months

6 months
Additional instrument 1
Additional instrument 2
Additional instrument 3
Additional instrument 4
Additional instrument 5
Treatment changes

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

MBC for depressive symptoms only
1 of 2
MBC for depressive and manic symptoms
1 of 2

Active Control

Experimental Treatment

30 Total Participants · 2 Treatment Groups

Primary Treatment: Measurement based care · No Placebo Group · N/A

MBC for depressive and manic symptoms
Experimental Group · 1 Intervention: Measurement based care · Intervention Types: Other
MBC for depressive symptoms only
ActiveComparator Group · 1 Intervention: Measurement based care · Intervention Types: Other

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 6 months

Who is running the clinical trial?

University of WashingtonLead Sponsor
1,587 Previous Clinical Trials
1,567,193 Total Patients Enrolled
National Institute of Mental Health (NIMH)NIH
2,528 Previous Clinical Trials
1,816,601 Total Patients Enrolled
Mayo ClinicOTHER
2,896 Previous Clinical Trials
3,699,291 Total Patients Enrolled
Joseph Cerimele, MDPrincipal InvestigatorUniversity of Washington

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 23rd, 2021

Last Reviewed: November 29th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.